Stay updated on Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Sign up to get notified when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.

Latest updates to the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check41 days agoChange DetectedFooter Revision updated from v3.4.2 to v3.4.3; no changes to study content or data.SummaryDifference0.1%

- Check70 days agoChange DetectedAddition of Revision: v3.4.2 and removal of the government funding status notice appear to be site housekeeping; no changes to the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check77 days agoChange DetectedAdded a site-wide government funding status notice and updated the site revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check84 days agoChange DetectedShow glossary added; the QC criteria label text and capitalization changed (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and a site revision indicator shows 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.